Guinea-Bissau has officially halted a controversial hepatitis B virus (HBV) vaccine trial that had come under intense global scrutiny. The research project, which received $1.6 million in funding from the United States Centers for Disease Control and Prevention (CDC), aimed to study the impact of administering HBV vaccines at different intervals. However, the trial was suspended after critics raised significant ethical concerns regarding the decision to withhold standard, life-saving vaccinations from thousands of infants to facilitate the research.
A researcher associated with the project confirmed that the trial failed to secure the necessary government approval, describing the termination as a major setback for scientific endeavors in the region. The project, managed by the Bissau-based Bandim Health Project—a group linked to the University of Southern Denmark—planned to involve approximately 14,000 babies. The experimental design involved randomly assigning infants to receive the vaccine either at birth or after a six-week delay.
The controversy intensified in mid-October when the nation’s judicial police conducted a raid on the research group's facilities in the capital, Bissau. During the operation, authorities seized several batches of vaccines. Officials have stated that inquiries are ongoing to determine whether the researchers adhered to the country’s established safety standards, though government representatives have not provided formal comment on the status of the investigation.
The study was led by scientists Christine Stabell Benn and Peter Aaby, who have operated the Bandim Health Project in Guinea-Bissau since 1978. The pair has long focused on the unintended impacts of various vaccines, previously theorizing that inactivated virus vaccines could be linked to increased mortality. This stance has frequently put them at odds with global health bodies. Notably, the World Health Organization (WHO) had previously classified the trial as unethical, emphasizing that HBV vaccines are essential for newborns to prevent lifelong liver damage and cancer.
Experts argued that the study was fundamentally flawed in its ethics, particularly in a country like Guinea-Bissau, where one-fifth of the 2.2 million population lives with hepatitis B. Because the nation currently faces limitations in vaccine supply, the government typically authorizes shots at six weeks of age, with a national goal to move to birth-time administration by 2028. The researchers attempted to frame this interim period as a unique window to study the timing of immunizations, yet critics maintained that the research design knowingly denied infants a proven, life-saving medical intervention.
Former Health Minister of Guinea-Bissau, Magda Robalo, criticized the researchers for appearing to capitalize on the country's limited research oversight and public health infrastructure. She noted that the potential for long-term harm to children involved in the study outweighed the benefits of the data being collected. The controversy was further complicated by the fact that the trial was intended to be "open label," meaning researchers would have knowledge of which participants received the vaccine at birth and which were delayed.
The project had previously faced a temporary pause in January after the government launched a formal review in response to widespread public anger. As the investigation into the conduct of the Bandim Health Project continues, the future of this particular research endeavor remains uncertain. For now, the suspension stands as a significant development in the broader debate regarding the ethics of international medical trials conducted in developing nations.
Comments